Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Evidence xmlns="http://hl7.org/fhir">
<id value="367921"/>
<meta>
<versionId value="26"/>
<lastUpdated value="2025-08-18T13:22:42.074Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Evidence 367921</b></p><a name="367921"> </a><a name="hc367921"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 26; Last updated: 2025-08-18 13:22:42+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-non-comparative-evidence.html">NonComparativeEvidence</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>url</b>: <a href="https://fevir.net/resources/Evidence/367921">https://fevir.net/resources/Evidence/367921</a></p><p><b>identifier</b>: FEvIR Object Identifier/367921, FEvIR Linking Identifier/NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG000</p><p><b>name</b>: NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG000</p><p><b>title</b>: Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312</p><p><b>citeAs</b>: </p><div><p>Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367921. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367921. Computable resource at: https://fevir.net/resources/Evidence/367921#json.</p>
</div><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>QUARTET LDQT</p>
</div><p><b>note</b>: , </p><blockquote><div><p>Outcome Measure Population Description: Data are available on only 28 participants in the intervention group for the mental health T score.</p>
</div></blockquote><blockquote><div><p>Outcome Measure Denominator Units: Participants</p>
</div></blockquote><p><b>variableRole</b>: Population</p><p><b>observed</b>: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href="EvidenceVariable-370508.html">Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) (NCT03640312)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:">Least Squares Mean</span></p><p><b>quantity</b>: 1.28 score on a scale</p><h3>SampleSizes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>KnownDataCount</b></td></tr><tr><td style="display: none">*</td><td>29</td></tr></table><h3>AttributeEstimates</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Standard Deviation</span></td><td>7.48 score on a scale</td></tr></table></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
<valueCodeableConcept>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
<code value="active"/>
<display value="Active"/>
</coding>
</valueCodeableConcept>
</extension>
<url value="https://fevir.net/resources/Evidence/367921"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net/FOI"/>
<value value="367921"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG000"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<name
value="NCT03640312_secondaryOutcomeMeasure_7_Change_in_Physical_Health_T_score_OPEN_PROMIS_CLOSE_OG000"/>
<title
value="Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312"/>
<citeAs
value="Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367921. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367921. Computable resource at: https://fevir.net/resources/Evidence/367921#json."/>
<status value="active"/>
<author>
<name
value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
</author>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<description
value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<variableDefinition>
<description value="QUARTET LDQT"/>
<note>
<text
value="Outcome Measure Population Description: Data are available on only 28 participants in the intervention group for the mental health T score."/>
</note>
<note>
<text value="Outcome Measure Denominator Units: Participants"/>
</note>
<variableRole value="population"/>
<observed>
<identifier>
<type>
<text value="ClinicalTrials.gov Outcome Measurement Group Id"/>
</type>
<value value="OG000"/>
</identifier>
<display
value="Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."/>
</observed>
</variableDefinition>
<variableDefinition>
<variableRole value="outcome"/>
<observed>🔗
<reference value="EvidenceVariable/370508"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="NCT03640312-secondaryOutcome-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) (NCT03640312)"/>
</observed>
</variableDefinition>
<statistic>
<statisticType>
<text value="Least Squares Mean"/>
</statisticType>
<quantity>
<value value="1.28"/>
<unit value="score on a scale"/>
</quantity>
<sampleSize>
<knownDataCount value="29"/>
</sampleSize>
<attributeEstimate>
<type>
<text value="Standard Deviation"/>
</type>
<quantity>
<value value="7.48"/>
<unit value="score on a scale"/>
</quantity>
</attributeEstimate>
</statistic>
</Evidence>